- Cough, Mucus, and Respiratory Health: A Complete Guide - August 18, 2025
- Flogoprofen: what it's used for and how to take it - June 21, 2025
- What is Movicol oral solution in sachet used for and how to take it? - June 18, 2025
In a pioneering effort that could transform the understanding of diseases such as he cancer and dementia, a strategic alliance between the British Government, Oxford Nanopore Technologies, UK Biobank, NHS England and Genomics England will carry out an ambitious project to create the first "epigenetic map" of the human genome.
Genetic innovation at the service of global health
Oxford Nanopore's innovative sequencing technology will analyse 50,000 samples from the UK Biobank, the most advanced data resource for medical research. This analysis will enable the creation of the first comprehensive dataset on epigenetic modifications in the human genome, a key resource for unraveling the root causes of devastating diseases.
Epigenetics, an emerging field of biology, studies how chemical modifications affect gene expression without altering the genetic code. According to experts, these modifications, which can be influenced by factors such as smoking or UV exposure, could be key to understanding why some people develop serious diseases while others remain healthy.
A leap towards more precise diagnoses and treatments with an “epigenetic map” of the human genome.
This groundbreaking project promises to provide new insights into diseases such as cancer, which remains one of the leading causes of death in the UK. Advances in epigenetics could open the door to earlier diagnoses and personalised treatments, giving hope to millions of patients and their families.
Gordon Sanghera, CEO of Oxford Nanopore, highlighted that “Capturing detailed epigenetic data will allow us to better understand the progression of diseases such as cancer and develop more effective treatments.”
For her part, the teacher Naomi Allen, chief scientist at the UK Biobank, stressed that this project will significantly expand the database available to researchers, combining epigenetic data with genetic, imaging and lifestyle information to obtain a comprehensive view of diseases.
A model of collaboration and trust in UK science
Made possible by a strategic partnership between multiple key players, this project reinforces the UK's leadership in life sciences. It is also part of the 10-year Health Plan, which seeks to transform the health system from a disease-based model to one focused on prevention.
The Secretary of Science and Technology, Peter Kyle, stated that "This breakthrough, made possible by collaboration between the government, the NHS and leading researchers, will save lives and keep families together for longer."
Long-term economic and scientific impact
The recent £40m government investment in a Proof of Concept Fund will boost the creation of start-ups based on academic research, replicating the success of Oxford Nanopore, founded in 2005 at the University of Oxford. This initiative will not only foster economic growth, but will consolidate the UK's role as a leader in scientific innovation.
Future prospects
Epigenetic mapping could be a milestone in global medical research, helping to better understand age-related diseases and developing innovative solutions to prevent and treat them. This initiative promises a significant impact not only on science, but also on the lives of millions of people.
